<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[avastin Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/avastin.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to avastin]]></description>
	<s:counts start="0" returned="20" found="21" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Genentech Finds No Friends in Lucentis Pricing Flap]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000194/genentech-finds-no-friends-in-lucentis-pricing-flap/]]></link>
		<description><![CDATA[Negative public opinion just keeps piling on to Genentech regarding its pricing policy on Lucentis and Avastin. This weekend saw a big Associated Press story describe how the company is refusing to ask the FDA to approve Avastin for use in treating "wet age-related macular degeneration," an eye condition that...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 02 Sep 2008 13:45:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="tickers">DNA</category>
	</item>
	<item>
		<title><![CDATA[As Roche Looks on, Genentech's Big Avastin Study Attracts Critics]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000182/as-roche-looks-on-genentechs-big-avastin-study-attracts-critics/]]></link>
		<description><![CDATA[A handful of scientists are skeptical that Genentechâ€™s C-08 trial of its Avastin anti-cancer drug will show any benefit in preventing the recurrence of colorectal cancer following surgery, reports PharmaWire via the Financial Times.    Avastin is one of Genentech's most valuable products, and currently rakes in sales...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 21 Aug 2008 15:28:40 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/roche+holding+ag.html"><![CDATA[Roche Holding AG]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/c-08.html"><![CDATA[C-08]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="tickers">DNA</category>
	</item>
	<item>
		<title><![CDATA[Doctors vs. Drug Companies: Pharma is Winning -- So Far]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000126/doctors-vs-drug-companies-pharma-is-winning-so-far/]]></link>
		<description><![CDATA[Earlier this week, the WSJ noted that oncologists are getting squeezed on the cost of expensive cancer drugs. Although the story features the usual anecdotes of doctors whose practices are in debt or who are shunting patients off to hospitals for treatment in order to save money, itâ€™s still hard...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 10 Jul 2008 13:05:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/health+care.html"><![CDATA[Health Care]]></category>
		<category domain="http://resources.bnet.com/topic/drug.html"><![CDATA[Drug]]></category>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/insurance.html"><![CDATA[Insurance]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+insurance.html"><![CDATA[Corporate Insurance]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
	</item>
	<item>
		<title><![CDATA[FDA Slaps Down Genentech On Eye Drug]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000102/fda-slaps-down-genentech-on-eye-drug/]]></link>
		<description><![CDATA[The saga of Avastin and Lucentis -- two Genentech drugs used to treat a blinding condition called age-related macular degeneration, even though one is about 50 times cheaper than the other -- is one of those stories that just gets better the longer it goes on.    A...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 17 Jun 2008 20:02:07 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="tickers">DNA</category>
	</item>
	<item>
		<title><![CDATA[Genentech Provides Update on "AVAiL" Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung Cancer]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_April_21/ai_n25337033]]></link>
		<description><![CDATA[SOUTH SAN FRANCISCO, Calif. -- Genentech, Inc. (NYSE:DNA) today announced an update for the previously reported Roche-sponsored international Phase III clinical study AVAiL of Avastin([R]) bevacizumab in combination with gemcitabine and cisplatin chemotherapy, in patients with advanced, non-squamous, non-small cell lung cancer NSCLC. The update confirmed the clinically and statistically...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 21 Apr 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="tickers">DNA</category>
	</item>
	<item>
		<title><![CDATA[Avastin's Use in Treatment of Metastatic Breast Cancer Expected to Increase Dramatically on Heels of FDA's Accelerated Approval, According to Study by GfK Market Measures]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_March_10/ai_n24380993]]></link>
		<description><![CDATA[Research suggests Avastin's market share will more than double in both first- and second-line therapy use in patients with HER2 negative metastatic breast cancer]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 10 Mar 2008 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Feb_22/ai_n24320776]]></link>
		<description><![CDATA[SOUTH SAN FRANCISCO, Calif. -- Genentech, Inc. (NYSE:DNA) today announced that the U.S. Food and Drug Administration FDA granted accelerated approval for Avastin([R]) bevacizumab, in combination with paclitaxel chemotherapy, for the treatment of patients who have not received chemotherapy for their metastatic HER2-negative breast cancer. The approval is based on...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 22 Feb 2008 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Non-Hodgkin's Lymphoma - Is There Room to Emulate Rituxan's Success?]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_Feb_20/ai_n24268804]]></link>
		<description><![CDATA[NEW YORK -- Reportlinker.com announces that a new market research report related to the Pharmaceutical industry is available in its catalogue.  Stakeholder Opinions: Non-Hodgkin's Lymphoma - Is there room to emulate Rituxan's success?  To order this report:  www.reportlinker.com/p074966/2008/02/Stakeholder-Opinions- Non-Hodgkins-Lymphoma---Is-there-room-to-emulate-Rituxans-success.html  Non-Hodgkin's lymphoma NHL is the most common...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 20 Feb 2008 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/nhl.html"><![CDATA[NHL]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[therapy]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Genentech Announces Resubmission of Supplemental Biologics License Application for Avastin in Combination with Paclitaxel for First-Line Metastatic Breast Cancer]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_August_24/ai_n27354660]]></link>
		<description><![CDATA[SOUTH SAN FRANCISCO, Calif. -- Genentech, Inc. (NYSE:DNA) announced today that the company resubmitted a supplemental Biologics License Application sBLA to the U.S. Food and Drug Administration FDA for Avastin([R]) bevacizumab, in combination with paclitaxel chemotherapy, for patients who have not received chemotherapy for their locally recurrent or metastatic breast...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 24 Aug 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="tickers">DNA</category>
	</item>
	<item>
		<title><![CDATA[Drug doubles survival rate among kidney cancer patients: study]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_kmafp/is_200706/ai_n19190784]]></link>
		<description><![CDATA[CHICAGO AFP &#8212; Anticancer drug Avastin, used for treating lung and colon cancer, has led to the doubling of the survival rate of people affected by kidney cancer, according to a new study released Saturday.  The study, which surveyed 649 patients worldwide, showed that those who received Avastin, also...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Sun, 03 Jun 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agence+france-presse.html"><![CDATA[Agence France-Presse]]></category>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Peregrine's Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models According to Data Presented.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5243/is_200704/ai_n19533434]]></link>
		<description><![CDATA[M2 PRESSWIRE-17 April 2007-Headline Maker: Peregrine's  Selective Anti-VEGF Antibodies are as Effective as AvastinR in  Preclinical Cancer Models According to Data PresentedC1994-2007 M2  COMMUNICATIONS LTD    RDATE:17042007    Market Gainer is quickly emerging as the one stop shop for  international small-cap investors...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 17 Apr 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/investor.html"><![CDATA[investor]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[SECURITY]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="tickers">NDAQ</category>
	</item>
	<item>
		<title><![CDATA[Briton sells World Cup tickets to buy cancer drug]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_kmafp/is_200606/ai_n16552425]]></link>
		<description><![CDATA[LONDON AFP &#8212; A young cancer sufferer has said he had been forced into selling his World Cup semi-final tickets to raise cash for his treatment.  Pharmacy student Nicholas Keher, 23, from Formby, near Liverpool in northwest England, was diagnosed with bowel cancer in February.  The drug Avastin,...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 22 Jun 2006 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agence+france-presse.html"><![CDATA[Agence France-Presse]]></category>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/britain.html"><![CDATA[Britain]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Genentech's Profit Up 48 Pct. on Backs of Cancer Patients; FTCR Calls for Fair Pricing of Drugs Developed with Taxpayer Grants]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5554/is_200604/ai_n21871233]]></link>
		<description><![CDATA[SANTA MONICA, Calif., April 11 /U.S. Newswire/ -- Genentech posted a 48 percent profit increase today for the first quarter of 2006 following a recent announcement that the company would double the price of its cancer drug Avastin, to over $100,000 per yeSANTA MONICA, Calif., April 11 /U.S. Newswire/ --...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 11 Apr 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="tickers">DNA</category>
	</item>
	<item>
		<title><![CDATA[Medical Advances Brighten Outlook For NJ&#39;s Cancer Patients]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_qa5311/is_200604/ai_n21388638]]></link>
		<description><![CDATA[The number of cancer deaths in the U.S. has been declining for some 15 years, but only lately has the rate of decline begun to outpace U.S. population growth. Medical experts speculate that increased longevity of cancer patients is due to people smoking less and to their being diagnosed and...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Sat, 01 Apr 2006 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/cooper.html"><![CDATA[Cooper]]></category>
		<category domain="http://resources.bnet.com/topic/hospital.html"><![CDATA[hospital]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[therapy]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Genentech sets off-label price of Avastin at $100K]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_qa5351/is_200604/ai_n21389337]]></link>
		<description><![CDATA[GENENTECH HAS established the price for the off-label use of its colorectal cancer drug Avastin at $100,000. What has critics up in arms is not only the cost but also the message it sends. ]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Sat, 01 Apr 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="tickers">DNA</category>
	</item>
	<item>
		<title><![CDATA[Switzerland gives green light to new Roche cancer treatment]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_kmafp/is_200412/ai_n8606788]]></link>
		<description><![CDATA[BASEL, Switzerland AFP &#8212; The Swiss drug giant Roche said it had won approval in Switzerland for a new cancer drug Avastin and hoped to get the go-ahead in over 90 other countries, including the European Union, soon.  "The Swiss health authority Swissmedic has approved Avastin for the treatment...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 20 Dec 2004 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/agence+france-presse.html"><![CDATA[Agence France-Presse]]></category>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/roche+holding+ag.html"><![CDATA[Roche Holding AG]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[SOFTWARE]]></category>
		<category domain="http://resources.bnet.com/topic/switzerland.html"><![CDATA[Switzerland]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Colon Cancer Drug Nears Approval after 34-Year Crusade.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5553/is_200402/ai_n22122279]]></link>
		<description><![CDATA[By Alice Dembner, The Boston Globe Knight Ridder/Tribune Business  News    Feb. 26--The first drug to emerge from a Harvard surgeon's  34-year  crusade for a new class of cancer treatments is expected to win  approval  within weeks from the Food and Drug Administration,...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 26 Feb 2004 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/dr..html"><![CDATA[Dr.]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[patient]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Genentech seeks early approval for oncology drug.(Life Sciences)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb4250/is_200310/ai_n13359464]]></link>
		<description><![CDATA[GENENTECH INC. is seeking early approval for its newest oncology  product Avastin bevacizumab with its filing of a completed biologics  license application with the Food and Drug Administration FDA last  week. The company is requesting priority re    GENENTECH INC. is seeking early approval for...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 06 Oct 2003 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/life+science.html"><![CDATA[life science]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="tickers">DNA</category>
	</item>
	<item>
		<title><![CDATA[Study Tests Two Targeted Therapies Against Advanced Breast Cancer.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5609/is_200306/ai_n23606522]]></link>
		<description><![CDATA[Byline: UCLA    LOS ANGELES, June 16 AScribe Newswire -- A new, early phase study  at UCLA's Jonsson Cancer Center for the first time pairs two  molecularly targeted drugs as a one-two punch to fight metastatic breast  cancer. The drugs attack only the cancer and...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 16 Jun 2003 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/cell.html"><![CDATA[cell]]></category>
		<category domain="http://resources.bnet.com/topic/therapy.html"><![CDATA[therapy]]></category>
		<category domain="http://resources.bnet.com/topic/university+of+california+at+los+angeles.html"><![CDATA[University of California at Los Angeles]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Genentech's Avastin poised for BLA. (Life Sciences).(biologics license application)]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb4250/is_200306/ai_n13212190]]></link>
		<description><![CDATA[GENENTECH INC. reported positive Phase III trial data for its  anti-angiogenic drug Avastin bevacizumab in colorectal cancer,  positioning the company to file a biologics license application BLA  later this year.      GENENTECH INC. reported positive Phase III trial data for its  anti-angiogenic...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 09 Jun 2003 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/avastin.html"><![CDATA[Avastin]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/life+science.html"><![CDATA[life science]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="tickers">DNA</category>
	</item>
</channel>
</rss>
